Diagnosis and Management of Pneumocystis jirovecii Pneumonia (PCP)
Diagnostic Considerations
- The Centers for Disease Control and Prevention (CDC) recommends that patients with a CD4 count of less than 200 cells/µL should be considered for PCP prophylaxis, as this population is at high risk for PCP 1, 2
- Classic PCP presentation includes fever, dyspnea on exertion, and respiratory symptoms in severely immunocompromised patients, with a CD4 count of 120 cells/µL placing this patient at high risk 1
- The presence of CT opacities is consistent with PCP, though the presentation can vary 3, 4
Differential Diagnoses
- Tuberculosis must be actively excluded in any HIV-positive patient with pneumonia, given the increased incidence of TB in this population, and three sputum specimens for AFB smear and culture should be obtained immediately 3, 4
- Bacterial pneumonia is also in the differential, as HIV-infected patients have increased rates of bacterial pneumonia, particularly with Streptococcus pneumoniae, and typically presents with more acute onset, focal consolidation on exam and imaging, and elevated WBC count 3, 5
Immediate Management
- The CDC recommends first-line therapy with trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day (based on trimethoprim component) divided into 3-4 doses for 21 days 1, 2
- Adjunctive corticosteroids should be added if PaO2 is less than 70 mmHg on room air, or alveolar-arterial oxygen gradient is greater than 35 mmHg 3, 6
Secondary Prophylaxis and Long-term Management
- After completing acute treatment, this patient requires lifelong PCP prophylaxis, with the preferred regimen being TMP-SMX one double-strength tablet daily 1, 2
- The CDC recommends initiating or optimizing antiretroviral therapy (ART) to improve immune function and reduce the risk of future opportunistic infections 7, 2